Peter Hagell1, Albert Westergren2, Shorena Janelidze3, Oskar Hansson3,4. 1. The PRO-CARE Group, School of Health and Society, Kristianstad University, 291 88, Kristianstad, Sweden. Peter.Hagell@hkr.se. 2. The PRO-CARE Group, School of Health and Society, Kristianstad University, 291 88, Kristianstad, Sweden. 3. Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden. 4. Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Abstract
PURPOSE: SCOPA-SLEEP is a rating scale for night-time sleep and daytime sleepiness (DS) proposed for use among people with Parkinson's disease (PD) as well as others. We translated it into Swedish and assessed its psychometric properties in PD and age-matched healthy controls. METHODS: Following translation according to the dual-panel approach, the Swedish SCOPA-SLEEP was field-tested regarding comprehensibility, relevance and respondent burden (n = 20). It was then psychometrically tested according to classical test theory (data completeness, scaling assumptions, targeting, reliability and construct validity) using data from 149 people with PD and 53 age-matched healthy controls from the prospective Swedish BioFINDER study. RESULTS: SCOPA-SLEEP took a mean of 3.5 min to complete and was considered easy to use and relevant. Missing item responses were <8 %, corrected item-total correlations were ≥0.47 (except for one DS item among controls), factor analyses suggested one dimension per scale, floor/ceiling effects were ≤17 %, reliability was ≥0.85 except for the DS scale among controls (0.65) and construct validity was supported. CONCLUSIONS: Observations concur with previous evaluations, thus providing initial support for the Swedish SCOPA-SLEEP among people with PD. Further studies are needed to establish its generic properties and to understand its measurement properties in better detail.
PURPOSE:SCOPA-SLEEP is a rating scale for night-time sleep and daytime sleepiness (DS) proposed for use among people with Parkinson's disease (PD) as well as others. We translated it into Swedish and assessed its psychometric properties in PD and age-matched healthy controls. METHODS: Following translation according to the dual-panel approach, the Swedish SCOPA-SLEEP was field-tested regarding comprehensibility, relevance and respondent burden (n = 20). It was then psychometrically tested according to classical test theory (data completeness, scaling assumptions, targeting, reliability and construct validity) using data from 149 people with PD and 53 age-matched healthy controls from the prospective Swedish BioFINDER study. RESULTS:SCOPA-SLEEP took a mean of 3.5 min to complete and was considered easy to use and relevant. Missing item responses were <8 %, corrected item-total correlations were ≥0.47 (except for one DS item among controls), factor analyses suggested one dimension per scale, floor/ceiling effects were ≤17 %, reliability was ≥0.85 except for the DS scale among controls (0.65) and construct validity was supported. CONCLUSIONS: Observations concur with previous evaluations, thus providing initial support for the Swedish SCOPA-SLEEP among people with PD. Further studies are needed to establish its generic properties and to understand its measurement properties in better detail.
Authors: Angelo Swaine-Verdier; Lynda C Doward; Peter Hagell; Hanne Thorsen; Stephen P McKenna Journal: Value Health Date: 2004 Sep-Oct Impact factor: 5.725
Authors: Young Hee Sung; Hee Jin Kim; Seong Beom Koh; Joong Seok Kim; Sang Jin Kim; Sang Myung Cheon; Jin Whan Cho; Yoon Joong Kim; Hyeo Il Ma; Mee Young Park; Jong Sam Baik; Phil Hyu Lee; Sun Ju Chung; Jong Min Kim; In Uk Song; Han Joon Kim; Ji Young Kim; Do Young Kwon; Jae Hyeok Lee; Jee Young Lee; Ji Seon Kim; Ji Young Yun; Jin Yong Hong; Mi Jung Kim; Jinyoung Youn; Ji Sun Kim; Eung Seok Oh; Hui Jun Yang; Won Tae Yoon; Sooyeoun You; Kyum Yil Kwon; Hyung Eun Park; Su Yun Lee; Younsoo Kim; Hee Tae Kim; Tae Beom Ahn Journal: J Korean Med Sci Date: 2018-01-08 Impact factor: 2.153